Drug Profile
Research programme: RNA-based tuberculosis therapies - Sarepta Therapeutics/Karolinska Institutet
Alternative Names: Bacterial PPMO for TB - Sarepta TherapeuticsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator AVI BioPharma; Karolinska Institute
- Developer Karolinska Institute; Sarepta Therapeutics
- Class RNA
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Tuberculosis in Sweden (Parenteral)
- 04 Nov 2017 No recent reports of development identified for research development in Tuberculosis in USA (Parenteral)
- 12 Jul 2012 Early research is ongoing in the US and Sweden